
NeoGenomics, Inc. (NASDAQ:NEO) shares are getting hammered Tuesday after the cancer diagnostics company announced the abrupt resignation of CEO Mark Mallon and warned of the first-quarter shortfall while also withdrawing its full-year guidance.
The NeoGenomics Analyst: BofA Securities analyst Derik de Bruin downgraded NeoGenomics shares from Buy to Neutral and reduced the price target from $25 to $18.